Ruxolitinibwani nau'in maganin ciwon daji ne da aka yi niyya. Ana amfani da shi musamman don hana kunna hanyar siginar JAK-STAT da rage siginar da ke hana haɓakar rashin daidaituwa, don haka samun sakamako na warkewa. Yana aiki ta hanyar toshe jikinka daga samar da abubuwan da ake kira abubuwan girma. Ba wai kawai zai iya warkar da cutar guda ɗaya ba a yankin hematology therapeutic area, amma kuma yana kula da neoplasms na myeloproliferative na gargajiya (wanda ake kira BCR-ABL1-negative MPNs), JAK exon 12 maye gurbi, CALR, da APL, da sauransu.
Menene shawarar farawa farawa?
Yana iya haifar da sakamako masu illa ciki har da myelosuppression kuma, wanda ke haifar da wuya, amma yiwuwar bayyanar asibiti mai tsanani kamar neutropenia, thrombocytopenia, cutar sankarar bargo da anemia. Don haka dole ne a ba da kulawa ta musamman wajen tantance yawan allurai lokacin da ake ba marasa lafiya. Shawarar farawa na Ruxolitinib ya dogara ne akan adadin PLT na majiyyaci. Ga marasa lafiya waɗanda adadin platelet ya fi 200, adadin farawa shine 20 MG sau biyu a rana; ga waɗanda ke da adadin platelet a cikin kewayon 100 zuwa 200, adadin farawa shine 15 MG sau biyu a rana; Ga marasa lafiya da adadin platelet tsakanin 50 zuwa 100, matsakaicin adadin farawa shine 5 MG sau biyu a rana.
Kariya kafin ɗaukaRuxolitinib
Da fari dai, zaɓi likita tare da ƙwararrun ƙwarewa a cikin jiyya tare da Ruxolitinib. Faɗa wa likitan ku idan kuna da rashin lafiyarsa, ko kuma idan kuna da wani rashin lafiyan. Yana iya ƙunsar sinadarai marasa aiki, waɗanda zasu iya haifar da rashin lafiyan halayen ko wasu matsaloli.
Na biyu, a kai a kai gwada kirga PLT. Dole ne a rubuta cikakken ƙididdigar jini da adadin platelet a kowane mako 2-4 tun lokacin shan Ruxolitinib har sai an daidaita allurai, sannan a gwada idan alamun asibiti na buƙatar haka.
Na uku, daidaita allurai da kyau. Ba kasafai ake daidaita kashi na farawa ba idan kun ɗauki Ruxolitinib amma kuna da ƙarancin ƙididdiga na platelet a farkon. Lokacin da adadin PLT ɗin ku ya karu yayin da aka yi niyya na haɗin kai, zaku iya ƙara yawan adadin ku a hankali ta bin umarnin likitan ku a hankali.
A ƙarshe, gaya wa likitan ku tarihin likitan ku, musamman na cututtukan myeloproliferative kamar cutar koda, cutar hanta, da ciwon daji na fata. Wasu magunguna ko jiyya dole ne su maye gurbin Ruxolitinib idan ba ku dace da shi ba.
Lokacin aikawa: Afrilu-25-2022